Navigation Links
Diatos Announces Positive Clinical Results for its DTS-201,Doxorubicin Prodrug Program

PARIS--(BUSINESS WIRE)--Jun 4, 2007 - Diatos SA, an international biopharmaceutical company focusing on the research, development and commercialization of targeted anti-cancer drugs, today announced that they presented data from a Phase I clinical trial of their anti-cancer compound, DTS-201, at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA.

DTS-201 is a doxorubicin prodrug developed for the targeted treatment of several solid cancers, including chemo-resistant tumors. The product is activated by enzymes specific to the tumor environment. During its Phase I clinical trial, DTS-201 was shown to be well tolerated and able to deliver high doses of free doxorubicin in humans.

The purpose of the DTS-201 Phase I clinical study is to assess the product's Maximum Tolerated Dose (MTD), safety profile and pharmacokinetic profile in patients with advanced or metastatic solid tumors. In a poster presentation entitled "Results of a Phase I study of DTS-201, a peptidic prodrug of doxorubicin in patients with solid tumors (Abstract # 2547)", researchers concluded that:

-- DTS-201 was well tolerated by twenty-five cancer patients treated with doses of up to 400 mg/m2 every three weeks. This corresponds to 3.75 times the standard dose of doxorubicin;

-- DTS-201 was safe and well tolerated at cumulative doses of up to 2750 mg/m2;

-- Evidence of clinical efficacy was observed: two patients showed partial responses and three patients with chemo-resistant tumors showed disease stabilisation;

-- The recommended dose for Phase II clinical trials is 400 mg/m2.

The high levels of tolerance to the product and positive clinical responses observed during this Phase I trial strongly support an assessment of the efficacy of DTS-201 in a Phase II study.

"DTS-201 is a safe and active compound which allowed delivery of a high dose of doxorubicin with
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:5/16/2008)...RK, May 16 /- Pulmo BioTech...details of the methodology and,purpose of its Phas...ing,technology for the diagnosis of Pulmonary Embo...e carried out by the Pulmo BioTech subsidiary,Pul...se I Study of the Use,of PulmoBind for Molecular I...
(Date:5/16/2008)..., Mass., May 16 /- BioVex Inc, a biot...ts in oncology and infectious,disease, announced t...lts,from its Phase II clinical trial of OncoVEX GM...ble at the American Society of Clinical Oncology,(...summary of the abstract,which describes the data a...
(Date:5/16/2008)...N, N.J., May 16 /- Veridex, LLC annou...tory Corporation of America Holdings,(LabCorp), ha...t for,prostate cancer. The new assay uses the biol...e cancer, detecting the methylation of the gene,GS...curs primarily in,cancer. Veridex is developing th...
(Date:5/15/2008)...IFF LAKE, N.J., May 15 /- Eisai Corpo...ts from 16 clinical data abstracts about,compounds...olio and,preclinical oncology research have been a...g of the American Society of Clinical Oncology (AS..., 2008., A wide variety of abstracts on Eisai mar...
Breaking Medicine Technology:Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 2Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 3BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Ozone Breaks Down Lungs Defenses 2494 1New test could help consumers avoid surprise headaches from chocolate wine 622 1New test could help consumers avoid surprise headaches from chocolate wine 622 2New test could help consumers avoid surprise headaches from chocolate wine 622 3San Diego Dentist Haunted by Smiles in Dominican Republic 2492 1San Diego Dentist Haunted by Smiles in Dominican Republic 2492 2Pure 26 Natural 3A Introducing an Effective Healthy Approach to Personal Care and Beyond 2490 1Pure 26 Natural 3A Introducing an Effective Healthy Approach to Personal Care and Beyond 2490 2Pure 26 Natural 3A Introducing an Effective Healthy Approach to Personal Care and Beyond 2490 3
...yer HealthCare,Pharmaceuticals announced today the...R) (interferon beta-1b), presented this week,at th...l Meeting,demonstrating early efficacy, long-term...treatment in patients with relapsing,forms of mult...s highlight the important clinical,benefits and lo...
...e, EDMONTON, May 02, 2007 /PRNewswire-FirstCall/ -...Quest is pleased to provide an,update on the pre-c...prostate cancer. , Prostate cancer is the second l...approximately 230,000 new cases and 30,000 deaths,...ized prostate,cancer are associated with significa...
Other Medicine Technology:Studies Presented at Neurology Conference Highlight Early Efficacy,Long-Term Tolerability, and High Patient Satisfaction with,Betaseron 2Studies Presented at Neurology Conference Highlight Early Efficacy,Long-Term Tolerability, and High Patient Satisfaction with,Betaseron 3Studies Presented at Neurology Conference Highlight Early Efficacy,Long-Term Tolerability, and High Patient Satisfaction with,Betaseron 4Quest PharmaTech's Prostate Cancer Program Update 2Quest PharmaTech's Prostate Cancer Program Update 3
(Date:5/16/2008)...T BEACH, Calif., May 16 /PRNewswire-FirstCall/ -- ...nnounced today the promotion of David,M. Boitano t...cer. "Dave,has made a tremendous contribution to N... strong investment growth and diversification stra... $1 billion in accretive,investments for NHP, leve...
(Date:5/16/2008)...EGO, May 16 /PRNewswire-FirstCall/ -- CryoCor, Inc... on the treatment of cardiac,arrhythmias, announce...f,CryoCor common stock filed a complaint in the Su... San Diego, naming as defendants each member of th...n Scientific Corporation.,The complaint is styled ...
(Date:5/16/2008)...guidelines quickly disseminated to community physi...ealthDay News) -- Partnerships between major acade...uick and effective way to spread cancer treatment ...er in Philadelphia. , Most new cancer treatment...ancer care is provided at community hospitals, not...
(Date:5/16/2008)...ch in some early stage cases makes therapy of litt..., May 16 (HealthDay News) -- Colon cancer patients...to receive chemotherapy. In fact, not only does ch...may actually harm them, a new study found. , "If..., then you should not be treated with chemotherapy...
Breaking Medicine News(10 mins):Health News:David M. Boitano Promoted to Senior Vice President 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 3Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 4Health News:Partnerships Effective Communicators of Cancer Advances 2Health News:Not All Colon Cancer Patients Need Chemotherapy: Study 2
...nization (WHO) Thursday expressed alarm over the g...on motorcycles in Asia//, warning that the situati...oted that young motorcyclists make up a significan...lities among road users in many Asian countries, s...
...n the benefits of a key ingredient in Cannabis, wh... had shown that cannabis could help fight brain, p...was found to inhibit lung tumor growth by 50%, dur...ce, suggesting that THC could be having a therapeu...
...h workers should focus their efforts on strengthen...access to antiretroviral drugs// will not overcome...d Health Organization's HIV/AIDS Department, and M...S, said on Tuesday during a press conference in Lo...
...nsumer interests and those of the pharmaceutical i...US Senate Committee approved// a bill that would c...necessary powers to require drug makers to wait tw...ved drug directly to consumers. The measure would...
Other Medicine News:Health News:U.N. Officials Call on Countries To Strengthen HIV/AIDS Prevention Efforts 2Health News:Moratorium Proposed on Advertisements of Newly Approved Drugs 2
This remarkable anti-reflux valve is enclosed in a hard plastic housing which prevents the valve from being accidentally held closed when in sitting or reclining positions. The valve is virtually sel
Intermittent catheter - Ready-to-Use Sterile, Enclosed System
The Medtronic® Resting Heart™ System offers a new approach to reducing cardiac surgery morbidity.
The Multiple Perfusion set provides simultaneous perfusion of the aortic root and up to three or more vein grafts. The set features an inlet port with female luer and clamp attached to an adapter whi
Medicine Products: